Treatment for familial amyotrophic lateral sclerosis/motor neuron disease (Q24241570)

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A pilot trial of dextromethorphan in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A randomized controlled trial of resistance exercise in individuals with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Lithium delays progression of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Xaliproden in amyotrophic lateral sclerosis: early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Thalidomide causes sinus bradycardia in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Transfer factor is ineffective in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Therapeutic trial of tilorone in ALS: Lack of benefit in a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Minocycline in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Recombinant growth hormone treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Double-blind study of modified neurotoxin in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Phase 2 study of sodium phenylbutyrate in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Motor cortex stimulation for ALS: a double blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Epidemiology of motor neuron disease in northern Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Motor neuron disease in Cantabria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Onset, natural history and outcome in idiopathic adult motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Genetics of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006153.PUB2

Randomized controlled phase II trial of glatiramer acetate in ALS

21 January 2018

1 reference

12 December 2020

The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials

1 reference

12 December 2020

Treatment of ALS with high dose pulse cyclophosphamide

1 reference

12 December 2020

Trial of oral physostigmine in amyotrophic lateral sclerosis

1 reference

12 December 2020

Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis

1 reference

12 December 2020

The administration of guanidine in amyotrophic lateral sclerosis

1 reference

12 December 2020

Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis

1 reference

12 December 2020

Can nimodipine affect progression of motor neuron disease? A double-blind pilot study

1 reference

12 December 2020

A double-blind placebo-controlled trial ofl-threonine in amyotrophic lateral sclerosis

1 reference

12 December 2020

Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian ALS Study Group

1 reference

12 December 2020

Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine.

1 reference

12 December 2020

A clinical trial of dextromethorphan in amyotrophic lateral sclerosis

1 reference

12 December 2020

Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation

1 reference

12 December 2020

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group

1 reference

12 December 2020

Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis

1 reference

12 December 2020

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

1 reference

12 December 2020

Prevalence of SOD1 mutations in the Italian ALS population

1 reference

12 December 2020

Trial of octacosanol in amyotrophic lateral sclerosis

1 reference

12 December 2020

Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis

1 reference

12 December 2020

Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness

1 reference

12 December 2020

A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis.

1 reference

12 December 2020

Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials

1 reference

12 December 2020

The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

12 December 2020

Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis

1 reference

12 December 2020

Trial of celecoxib in amyotrophic lateral sclerosis

1 reference

12 December 2020

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

1 reference

12 December 2020

A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis

1 reference

12 December 2020

A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group

1 reference

12 December 2020

Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis

1 reference

12 December 2020

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

12 December 2020

[Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes].

1 reference

12 December 2020

Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group

1 reference

12 December 2020

Acute action of aminophylline in patients with amyotrophic lateral sclerosis

1 reference

12 December 2020

Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis

1 reference

12 December 2020